[Zhifei Bio: Pandemic influenza virus mRNA vaccine clinical trial application accepted] On November 6, Zhifei Bio (300122.SZ) announced that the pandemic influenza virus mRNA vaccine developed by the company's wholly-owned subsidiary Zhifei Longkoma has received a notice of acceptance of the drug clinical trial application from the State Food and Drug Administration. The vaccine is intended to be used for pandemic influenza vaccination and is developed based on the company's independent mRNA technology platform. The preparation cycle is significantly shorter than that of traditional chicken embryo inactivated vaccines. As of the announcement date, no pandemic influenza virus mRNA vaccine has been officially approved for marketing in China. The company reminds that this acceptance will not have a significant impact on the company's recent performance, and there is uncertainty in the progress of subsequent clinical trials and product launch.